What the FDA labels say about taking them together
Carbamazepine and paliperidone
Carbamazepine's FDA label of August 20, 2026 names paliperidone in its drug interactions section, and paliperidone's label names carbamazepine too. The paliperidone label: “Avoid using CYP3A4 and/or P-gp inducers with INVEGA TRINZA during the 3-month dosing interval, if possible. If administering a strong inducer is necessary, consider managing the patient using paliperidone …”
Check it at the source: the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation); the paliperidone FDA label on DailyMed (effective January 31, 2025, Janssen Pharmaceuticals, Inc.).
What does the carbamazepine label say about paliperidone?
Carbamazepine label, drug interactions… doxycycline, eslicarbazepine, ethosuximide, everolimus, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, mianserin, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, paliperidone, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, sertraline, sirolimus, tadalafil, theophylline, tiagabine, topiramate, tramadol, trazodone, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.
Carbatrol label (Takeda Pharmaceuticals America, Inc., August 17, 2026), drug interactionsAcetaminophen, albendazole, alprazolam, aprepitant, buprenorphine, apixaban (6), bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, corticosteroids (e.g. prednisolone, dexamethasone), cyclosporin, dabigatran (6), delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, edoxaban (6), eslicarbazepine, ethosuximide, everolimus, felbamate, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuximide, midazolam, mirtazapine, nefazodone, nortriptyline, olanzapine, oral and other hormonal contraceptives (2), oxcarbazepine, paliperidone, phenytoin (3), praziquantel, protease …
Equetro label (Validus Pharmaceuticals LLC, August 19, 2025), drug interactionsDrugs metabolized by CYP3A4 or CYP1A2 include the following: Acetaminophen, albendazole, alprazolam, aprepitant, buprenorphone, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, paliperidone, phenytoin, praziquantel, quetiapine, risperidone, sertraline, sirolimus, tadalafil …
Source: FDA drug label (Carbatrol, NDA020712), Takeda Pharmaceuticals America, Inc., effective August 17, 2026 (SPL set bc03e499-5bac-4293-bff4-6864153a624d), via openFDA
Source: FDA drug label (Equetro, NDA021710), Validus Pharmaceuticals LLC, effective August 19, 2025 (SPL set be478f3c-40f6-47cc-8ab9-f420a9372b1c), via openFDA
Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed
What does the paliperidone label say about carbamazepine?
Paliperidone label, drug interactionsIt may be necessary to increase the dose of INVEGA when a strong inducer of both CYP3A4 and P-gp (e.g., carbamazepine) is co-administered.
Invega Sustenna label (Janssen Pharmaceuticals, Inc., February 14, 2025), drug interactionsAvoid using a strong inducer of CYP3A4 and/or P-gp (e.g., carbamazepine, rifampin, St John's Wort) during a dosing interval for INVEGA SUSTENNA.
Invega Trinza label (Janssen Pharmaceuticals, Inc, February 14, 2025), drug interactionsConcomitant Drug Name or Drug Class: Strong Inducers of CYP3A4 and P-gp (e.g., carbamazepine, rifampin, or St. John's Wort); Clinical Rationale: The concomitant use of paliperidone and strong inducers of CYP3A4 and P-gp may decrease the exposure of paliperidone [see ].; Clinical Recommendation: Avoid using CYP3A4 and/or P-gp inducers with INVEGA TRINZA during the 3-month dosing interval, if possible. If administering a strong inducer is necessary, consider managing the patient using paliperidone extended-release tablets [see ].
Source: FDA drug label (Invega Sustenna, NDA022264), Janssen Pharmaceuticals, Inc., effective February 14, 2025 (SPL set 1af14e42-951d-414d-8564-5d5fce138554), via openFDA
Source: FDA drug label (Invega Trinza, NDA207946), Janssen Pharmaceuticals, Inc, effective February 14, 2025 (SPL set c39e65d7-fa44-4e4c-8b12-a654d3ed0eae), via openFDA
Source: FDA drug label (INVEGA), Janssen Pharmaceuticals, Inc., effective January 31, 2025 (SPL set 7b8e5b26-b9e4-4704-921b-3c3c0d159916), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Carbamazepine | Paliperidone | |
|---|---|---|
| Labeled for | Bipolar disorder, Seizures and epilepsy | Schizophrenia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.119 per tablet 200 mg tablet | $0.972 per tablet 3 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once